Monday March 19, 2018
Home India Quotas for wo...

Quotas for women to reduce Gender Discrimination and to help them advance in Leadership Positions

The government is also committed to 33 per cent reservation in Parliamentary and State assemblies for women through a Constitutional amendment

Quotas for women
Women empowerment, wikimedia

New Delhi, Jan 13, 2017: In an attempt to reduce gender discrimination Union Minister Anupriya Patel today favoured establishing quotas for women. This will help them compete in mixed-gender environments and advance in leadership roles. This step is taken keeping in mind that companies and public offices with women at senior positions tend to do better.

NewsGram brings to you latest new stories in India.

While mentioning the other details she also said that the government is also committed to 33 per cent reservation in Parliamentary and State assemblies for women through a Constitutional amendment.

The Minister of State for Health and Family Welfare said here at an Assocham event that “Research has shown that companies perform better during economic turbulence when they have women on their boards, and communities with women in public offices have greater investment in public goods.”

Go to NewsGram and check out news related to political current issues.

Patel said that one of the effective ways to help women advance in leadership positions and enhance their decision-making role “could be establishing quotas,” although she did not specify the areas for establishing the quotas to women.

Look for latest news from India in NewsGram.

This can increase “women’s willingness to compete in competitive mixed-gender environments resulting in more qualified candidates, men and women alike, applying for competitive positions,” said Patel, who herself is an SRCC (Shri Ram College of Commerce) Graduate from Delhi University.

“Also, modelling female leadership can go a long way,” she added while addressing the BIMSTEC-SAARC Women’s Economic Forum organised by Assocham.

In order to build a stronger economic life across all sectors and achieve internationally agreed goals for development and sustainability, Patel has favoured this decision for empowering women.

 – prepared by Saptaparni Goon of NewsGram. Twitter: @saptaparni_goon

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Pentavalent vaccine: Doctors raise red flag

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive

the new Hepatitis B vaccine for adults is called Heplisav-B.
India's PV to be reexamined because of its harmful effects. .
  • Pentavalent vaccine was introduced in India six years ago
  • It is since then have been a cause of many deaths
  • Doctors want it to be reexamined before continuing its use

Pentavalent vaccine (PV), that was introduced by India a little over six years ago, doubled the deaths of children soon after vaccination compared to the DPT (Diphtheria-Pertussis-Tetanus) vaccine, according to a new study that calls for a “rigorous review of the deaths following vaccination with PV”.

Health officials have launched a campaign targeting nearly 24 million people with a one-fifth dose of the vaccine. Wikimedia Commons
PV has been cause of many deaths in past years. Wikimedia Commons

Government records show that there were 10,612 deaths following vaccination (both PV and DPT) in the last 10 years. There was a huge increase in these numbers in 2017, which the Health Ministry has promised to study. “The present analysis could be a starting point in the quest to reduce the numbers of such deaths,” authors of the new study say.

The study by Dr Jacob Puliyel, Head of Pediatrics at St Stephens Hospital, and Dr V. Sreenivas, Professor of Biostatistics at the All-India Institute of Medical Sciences (AIIMS), both in New Delhi, is published in the peer-reviewed Medical Journal of Dr D.Y. Patil University.

PV is a combination of the DPT vaccine and two more vaccines against Haemophilus influenza type B (Hib) and hepatitis B. Starting December 2011, PV was introduced into India’s immunisation programme to replace DPT vaccine in a staged manner with a view to adding protection against Hib and Hepatitis B without increasing the number of injections given to infants.

Doctors have raised concerns over these vaccines. Wikimedia Commons
Doctors have raised concerns over these vaccines. Wikimedia Commons

But sporadic reports of unexplained deaths following immunisation with PV had been a matter of concern. Puliyel, Sreenivas and their colleagues undertook the study to find out if these deaths were merely coincidental or vaccine-induced.

The authors obtained data of all deaths reported from April 2012 to May 2016 under the Right to Information Act. Data on deaths within 72 hours of administering DPT and PV from different states were used.

For their study, the authors assumed that all deaths within 72 hours of receiving DPT are natural deaths. Using this figure as the baseline, they presumed that any increase in the number of deaths above this baseline among children receiving PV must be caused by this vaccine.

Also Read: With Medicine Running Out, Venezuelans With Transplant Live in Fear

According to their analysis of the data provided by the government, there were 237 deaths within 72 hours of administering the Pentavalent vaccine — twice the death rate among infants who received DPT vaccine.

Extrapolating the data, the authors have estimated that vaccination of 26 million children each year in India would result in 122 additional deaths within 72 hours, due to the switch from DPT to PV.

“There is likely to be 7,020 to 8,190 deaths from PV each year if data from states with the better reporting, namely Manipur and Chandigarh, are projected nationwide,” their report says.

It is important to make sure that these vaccines are reexamined peroperly. VOA

The authors note that while the study looks at the short-term increase in deaths (within three days of vaccination) it does not calculate the potential benefits of PV on infant mortality, for example by protection against lethal diseases like Haemophilus influenza.

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive. “These findings of differential death rates between DPT and PV do call for further rigorous prospective population-based investigations,” the study concludes. IANS